Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists.
Yonina R Murciano-GoroffAnne Marie McCarthyMirar N BristolPeter GroeneveldSusan M DomchekU Nkiru MotanyaKatrina ArmstrongPublished in: Breast cancer research and treatment (2018)
Nearly one in five providers never or rarely ever ordered BRCA 1/2 testing for their breast cancer patients, and nearly 15% never or rarely ever ordered Oncotype DX. Less frequent ordering of BRCA 1/2 is associated with less frequent use of Oncotype DX testing, and vice versa. Those who do not order BRCA 1/2 testing report less positive attitudes toward genetic innovation. Further education of this subset of providers regarding the benefits of precision medicine may enable more rapid diffusion of genetic technology.